TWI255813B - Compounds for use as alphavbeta3 receptor antagonists - Google Patents

Compounds for use as alphavbeta3 receptor antagonists

Info

Publication number
TWI255813B
TWI255813B TW089118280A TW89118280A TWI255813B TW I255813 B TWI255813 B TW I255813B TW 089118280 A TW089118280 A TW 089118280A TW 89118280 A TW89118280 A TW 89118280A TW I255813 B TWI255813 B TW I255813B
Authority
TW
Taiwan
Prior art keywords
compounds
receptor antagonists
het
osteoporosis
useful
Prior art date
Application number
TW089118280A
Other languages
English (en)
Inventor
Peter J Manley
William Henry Miller
Irene N Uzinskas
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of TWI255813B publication Critical patent/TWI255813B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • External Artificial Organs (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW089118280A 1999-09-07 2000-09-25 Compounds for use as alphavbeta3 receptor antagonists TWI255813B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15278099P 1999-09-07 1999-09-07

Publications (1)

Publication Number Publication Date
TWI255813B true TWI255813B (en) 2006-06-01

Family

ID=22544416

Family Applications (1)

Application Number Title Priority Date Filing Date
TW089118280A TWI255813B (en) 1999-09-07 2000-09-25 Compounds for use as alphavbeta3 receptor antagonists

Country Status (29)

Country Link
EP (1) EP1218005B1 (zh)
JP (1) JP4685307B2 (zh)
KR (1) KR100711170B1 (zh)
CN (1) CN1236767C (zh)
AR (1) AR025589A1 (zh)
AT (1) ATE284870T1 (zh)
AU (1) AU768918B2 (zh)
BR (1) BR0013749A (zh)
CA (1) CA2384671A1 (zh)
CO (1) CO5200845A1 (zh)
CZ (1) CZ2002822A3 (zh)
DE (1) DE60016769T2 (zh)
EG (1) EG24179A (zh)
ES (1) ES2234658T3 (zh)
GC (1) GC0000203A (zh)
HK (1) HK1049110B (zh)
HU (1) HUP0202710A3 (zh)
IL (2) IL148325A0 (zh)
MX (1) MXPA02002455A (zh)
NO (1) NO322109B1 (zh)
NZ (1) NZ517296A (zh)
PE (1) PE20010582A1 (zh)
PL (1) PL200404B1 (zh)
PT (1) PT1218005E (zh)
TR (1) TR200200614T2 (zh)
TW (1) TWI255813B (zh)
UY (1) UY26329A1 (zh)
WO (1) WO2001017959A2 (zh)
ZA (1) ZA200201780B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
US6982263B2 (en) 2001-06-08 2006-01-03 Boehringer Ingelheim Pharmaceuticals, Inc. Nitriles useful as reversible inhibitors of cysteine proteases
GB0315509D0 (en) 2003-07-02 2003-08-06 Meridica Ltd Dispensing device
EP1721905A4 (en) * 2004-03-05 2009-11-18 Taisho Pharmaceutical Co Ltd THIAZOLE DERIVATIVE
CN103097385B (zh) 2010-07-14 2016-08-03 诺华股份有限公司 Ip受体激动剂杂环化合物
TW201335160A (zh) 2012-01-13 2013-09-01 Novartis Ag Ip受體激動劑之雜環化合物
CN105189500A (zh) 2013-02-13 2015-12-23 诺华股份有限公司 Ip受体激动剂杂环化合物
CN108675954A (zh) * 2018-04-03 2018-10-19 爱斯特(成都)生物制药股份有限公司 2-氨基-3-羟甲基吡啶的一种制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08325264A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規2−芳香環置換−3−フェニルプロピオン酸またはアクリル酸誘導体
JPH08325263A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規2−アミノ−3−フェニルプロピオン酸誘導体
JP2000502708A (ja) * 1995-12-29 2000-03-07 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗物質
AU8750298A (en) * 1997-08-28 1999-03-22 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
AR015446A1 (es) * 1997-09-19 2001-05-02 Smithkline Beecham Corp Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios
UY25421A1 (es) * 1998-03-10 2001-07-31 Smithkline Beecham Corp Antagonistas de receptor de vitronectina
WO2000009503A1 (en) * 1998-08-13 2000-02-24 Merck & Co., Inc. Integrin receptor antagonists

Also Published As

Publication number Publication date
AU768918B2 (en) 2004-01-08
UY26329A1 (es) 2001-07-31
EP1218005A4 (en) 2002-10-09
CN1236767C (zh) 2006-01-18
JP4685307B2 (ja) 2011-05-18
WO2001017959A3 (en) 2001-05-10
IL148325A0 (en) 2002-09-12
KR100711170B1 (ko) 2007-04-27
EG24179A (en) 2008-09-28
TR200200614T2 (tr) 2002-07-22
NO20021113D0 (no) 2002-03-06
DE60016769T2 (de) 2005-11-24
ES2234658T3 (es) 2005-07-01
GC0000203A (en) 2006-03-29
EP1218005B1 (en) 2004-12-15
CN1377269A (zh) 2002-10-30
MXPA02002455A (es) 2002-07-02
PE20010582A1 (es) 2001-06-23
CO5200845A1 (es) 2002-09-27
HK1049110A1 (en) 2003-05-02
NO322109B1 (no) 2006-08-14
ATE284870T1 (de) 2005-01-15
WO2001017959A2 (en) 2001-03-15
KR20020027624A (ko) 2002-04-13
AR025589A1 (es) 2002-12-04
CZ2002822A3 (cs) 2002-07-17
JP2003508516A (ja) 2003-03-04
BR0013749A (pt) 2003-06-10
IL148325A (en) 2007-06-03
NO20021113L (no) 2002-05-03
HK1049110B (zh) 2005-07-22
DE60016769D1 (de) 2005-01-20
PL354176A1 (en) 2003-12-29
PL200404B1 (pl) 2009-01-30
EP1218005A2 (en) 2002-07-03
AU7354300A (en) 2001-04-10
ZA200201780B (en) 2003-05-28
NZ517296A (en) 2003-11-28
HUP0202710A2 (hu) 2002-12-28
PT1218005E (pt) 2005-05-31
HUP0202710A3 (en) 2003-06-30
CA2384671A1 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
CZ305838B6 (cs) N-(2-arylethyl)benzylaminy jako antagonisté receptoru 5-HT6
NZ522326A (en) Adenosine A2A receptor antagonists
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
MY138086A (en) Novel urea derivative as vanilloid receptor-1 antagonist
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
NO20014363L (no) 4-okso-4,7-dihydro-tieno[2,3-b]pyridin-5-karboksamider som antivirale midler
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
GB0124933D0 (en) Chemical compounds
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
MXPA03002911A (es) Compuestos quimicos.
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
MXPA04005784A (es) 2-fenilbenzofuranos sustituidos como agentes estrogenitos.
NO20001514L (no) Vitronectin-reseptor-antagonist
TR200000786T2 (tr) Vitronektin reseptör antagonisti
NZ514542A (en) Vasopressin antagonists for the treatment of pulmonary hypertension
MY128896A (en) Pharmaceutical combinations
MXPA04006041A (es) Antivirales de piridoquinoxalina.
TW200508199A (en) Novel compound
AP1534A (en) Vitronectin receptor antagonists.
TWI255813B (en) Compounds for use as alphavbeta3 receptor antagonists
MXPA03002909A (es) Compuestos quimicos.
MXPA02012470A (es) Inhibidores de fosfodiesterasa especificos para gmp ciclico.
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees